Related Experiment Video
Updated: Aug 28, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
347
Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei
Ruiqing Ma1, Dongmei Lu2, Shilin Xue3
1Department of Myxoma, Aerospace Center Hospital, Beijing, China.
ANZ Journal of Surgery
|September 22, 2022
Summary
Preoperative systemic chemotherapy (PSC) for appendiceal pseudomyxoma peritonei (PMP) does not increase complications but offers no survival benefit. Patients undergoing cytoreductive surgery plus HIPEC without PSC showed better outcomes.
Area of Science:
- Surgical Oncology
- Gastrointestinal Oncology
- Peritoneal Malignancies
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy primarily originating from mucin-producing appendiceal tumors.
- Management often involves cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
Purpose of the Study:
- To evaluate the impact of preoperative systemic chemotherapy (PSC) on safety and survival in appendiceal PMP patients undergoing CRS + HIPEC.
- To compare outcomes between patients who received PSC and those who did not.
Main Methods:
- Retrospective analysis of 750 patients with appendiceal PMP treated between 2008 and 2019.
- Comparison of clinicopathological data, perioperative outcomes, and overall survival (OS) between PSC and non-PSC groups.
Main Results:
- PSC did not significantly increase major perioperative complications; blood loss >1000 mL was an independent risk factor for serious complications (P=0.026).
- Median OS was shorter in the PSC group (42 months) compared to the non-PSC group (67 months).
- In stratified analyses (PCI < 20, CC 0/1, low-grade), non-PSC patients consistently showed significantly better OS.
Conclusions:
- Preoperative systemic chemotherapy (PSC) is safe in appendiceal PMP patients undergoing CRS + HIPEC.
- PSC does not appear to improve postoperative survival and may be associated with worse outcomes in select patient subgroups.
Keywords:
cytoreductive surgerypreoperative systemic chemotherapyprognosispseudomyxoma peritoneisingle centerMore Related Videos
Related Concept Videos
01:29Appendicitis-II: Diagnostic Studies and Management
131
Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
131
01:22Appendicitis-I: Introduction
454
The appendix, a small, narrow, blind tube extending from the inferior part of the cecum, is widely regarded as a vestigial organ, having lost much of its original function through evolution. Despite its diminished role, the appendix can become inflamed, a condition known as appendicitis.
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
454